COMMUNIQUÉS West-GlobeNewswire
-
Doheny Eye Institute Experts to Share Groundbreaking Insights at the American Academy of Ophthalmology 2026 Annual Meeting
01/10/2026 -
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities
01/10/2026 -
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
01/10/2026 -
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
01/10/2026 -
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
01/10/2026 -
Crohn et Colite Canada investit 1,5 million de dollars dans la recherche sur les MII et les soins futurs
01/10/2026 -
Crohn’s and Colitis Canada Invests $1.5 Million to Advance IBD Research and Future Care
01/10/2026 -
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
01/10/2026 -
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
01/10/2026 -
Amplio Pharma Reports Positive Early Clinical Results for NovoBioJect, Designed to Make the World's Most-Used Rheumatoid Arthritis Drug Work for More Patients
01/10/2026 -
HealthEdge Launches Unified AI-Powered Platform to Guarantee Financial Outcomes for Health Plans
01/10/2026 -
Government of Saskatchewan proclaims October Health Literacy Month
01/10/2026 -
Michigan Contact Lens Opens 1-800-DRY-EYES Center in Expanded Southfield Facility
01/10/2026 -
Bloom Healthcare Brings Its Proven In-Home Care Model to Dallas-Fort Worth Seniors
01/10/2026 -
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10/2026 -
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
01/10/2026 -
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
01/10/2026 -
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
01/10/2026 -
MitoRx Therapeutics presents new preclinical data on MTRX31, demonstrating restored mitochondrial density, at the 62nd EASD Annual Meeting
01/10/2026
Pages